Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody.
Smith
Franz O
FO
Goff
Stephanie L
SL
Klapper
Jacob A
JA
Levy
Catherine
C
Allen
Tamika
T
Mavroukakis
Sharon A
SA
Rosenberg
Steven A
SA
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000628:therapy; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D007416:Intestinal Perforation / Q000139:chemically induced*; D000074324:Ipilimumab; D007680:Kidney Neoplasms / Q000628:therapy; D008545:Melanoma / Q000628:therapy
D000911:Antibodies, Monoclonal; D007376:Interleukin-2; D000074324:Ipilimumab